Treatment of prostatic carcinoma by gonadotropin inhibition with danazol. A preliminary report.
article
OA: closed
CC0
AI-generated summary
This preliminary report investigated the effect of oral danazol in five prostate cancer patients, observing marked reductions in gonadotropin and testosterone levels with encouraging clinical and cytological results after 16 weeks.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The effect of an oral gonadotropin agent--Danazol--on 5 patients with prostatic carcinoma was investigated. A phase 2 pilot study, using a combination of repeated clinical findings, hormone analyses and cytological examinations, allowed some assessment of results after 16 weeks. There was a marked fall in gonadotropin and testosterone serum levels in all patients. Despite a minor rate of cancer remission, results of clinical and cytological examinations were encouraging enough to stimulate further investigations.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- openalex
- last seen: 2026-05-10T10:56:25.982381+00:00
License: CC0
· commercial use OK